The Centre on Wednesday placed a second purchase order with the Serum Institute of India for the supply of one crore doses of Oxford-AstraZeneca COVID-19 vaccine Covishield', each costing Rs 210, including GST, sources said.
The HLL Lifecare Limited, a public sector undertaking, on behalf of the Union health ministry issued the supply order in the name of Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII), Pune.
The government had on January 11 placed an order for 1.1 crore doses of Covishield at a cost of Rs 231 crore, which has now risen to Rs 441 crore with the second order placed on Wednesday, a source said.
The government had on January 11 also committed to buy from the Serum Institute 4.5 crore doses of the vaccine, in addition to the first order of 1.1 crore doses.
India has approved two COVID-19 vaccines--Covishield manufactured by SII and indigenously developed Covaxin of Bharat Biotech--for restricted emergency use in the country.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)